What is Leerink Partnrs’ Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Tenax Therapeutics in a report issued on Wednesday, March 26th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will earn ($1.06) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($3.52) EPS, Q4 2025 earnings at ($4.73) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($4.86) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($1.03) EPS.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.34.

TENX has been the topic of several other research reports. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research note on Monday, March 10th. Finally, StockNews.com assumed coverage on Tenax Therapeutics in a research report on Saturday. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Trading Up 0.9 %

Tenax Therapeutics stock opened at $6.55 on Monday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The firm has a market capitalization of $26.00 million, a PE ratio of -1.23 and a beta of 2.20. The firm’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $5.46.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new position in shares of Tenax Therapeutics in the 4th quarter worth about $1,026,000. Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics in the third quarter worth approximately $101,000. Millennium Management LLC purchased a new stake in Tenax Therapeutics in the fourth quarter worth approximately $166,000. Two Sigma Investments LP bought a new position in Tenax Therapeutics during the fourth quarter valued at approximately $84,000. Finally, Geode Capital Management LLC raised its stake in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares in the last quarter. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.